Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMETA-Breast olaparib study in BRCA1/2 promoter-methylated advanced triple-negative breast cancer
2016-001407-23Phase 2Active
- Sponsor
- GEICAM
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in breast cancer and triple-negative breast cancer (TNBC), sponsored by GEICAM. Primary endpoint: Objective response rate. Started Dec 2016; status: active.
02
Drugs
olaparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-001407-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001407-23.